Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-Drug Anti-Angiogenic Regimen in Relapsed/Progressive Pediatric Cancer
NCT00357500Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2005
- Primary completion
- Feb 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide, celecoxib, fenofibrate, etoposide, cyclophosphamide in leukemia, lymphoma, Bone tumor (BT), neuroblastoma, glioma, sponsored by Dana-Farber Cancer Institute. Started Jan 2005; status: completed.
02
Drugs
thalidomidecelecoxibfenofibrateetoposidecyclophosphamide
03
Conditions
leukemialymphomaBone tumor (BT)neuroblastomaglioma
Beyond the preview
Go deeper on NCT00357500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00357500.